60 Results for "

human PPARγ

" in MedChemExpress (MCE) Product Catalog:
Products (60)

60 Results for "human PPARγ" in MCE Product Catalog:

53
53 Publications Verification
Cat. No.: HY-13956
CAS No.: 111025-46-8
Purity:  99.89%
Synonyms: U 72107
Target:  

PPAR Ferroptosis

Research Areas:  

Metabolic Disease Cancer

Pioglitazone (U 72107) is an orally active and selective PPARγ (peroxisome proliferator-activated receptor) agonist with high affinity binding to the PPARγ ligand-binding domain with EC50 of 0.93 and 0.99 μM for human and mouse PPARγ, respectively. Pioglitazone can be used in diabetes research .
loading...
    loading...
53
53 Publications Verification
Cat. No.: HY-14601
CAS No.: 112529-15-4
Purity:  99.97%
Synonyms: U 72107A; AD 4833
Target:  

PPAR Ferroptosis

Research Areas:  

Metabolic Disease Cancer

Pioglitazone hydrochloride is a potent and selective PPARγ agonist with EC50s of 0.93 and 0.99 μM for human and mouse PPARγ, respectively.
loading...
    loading...
38
38 Cited Publications
Cat. No.: HY-16995
CAS No.: 50892-23-4
Synonyms: Wy-14643
Target:  

PPAR

Pirinixic acid (Wy-14643) is a potent agonist of PPARα, with EC50s of 0.63 μM, 32 μM for murine PPARα and PPARγ, and 5.0 μM, 60 μM, 35 μM for human PPARα, PPARγ and PPARδ, respectively.
loading...
    loading...
36
36 Cited Publications
Cat. No.: HY-50935
CAS No.: 97322-87-7
Synonyms: CS-045
Research Areas:  

Metabolic Disease Cancer

Troglitazone is an orally active PPARγ agonist, with EC50s of 550 nM and 780 nM for human and murine PPARγ receptor, respectively. Troglitazone has anticancer activity, prevents and inhibits the development of type 2 diabetes.
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-13861
CAS No.: 265129-71-3
Purity:  99.45%
Target:  

PPAR

Research Areas:  

Cardiovascular Disease

GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-13928
CAS No.: 317318-84-6
Purity:  99.94%
Synonyms: GW610742
GW0742 is a potent PPARβ and PPARδ agonist, with an IC50 of 1 nM for human PPARδ in binding assay, and EC50s of 1 nM, 1.1 μM and 2 μM for human PPARδ, PPARα, and PPARγ, respectively.
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-B0637
CAS No.: 41859-67-0
Synonyms: BM15075
Target:  

PPAR

Bezafibrate is an agonist of PPAR, with EC50s of 50 μM, 60 μM, 20 μM for human PPARα, PPARγ and PPARδ, and 90 μM, 55 μM, 110 μM for murine PPARα, PPARγ and PPARδ, respectively; Bezafibrate is used as an hypolipidemic agent.
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-15655
CAS No.: 196808-24-9
Purity:  99.93%
Target:  

PPAR

GW 1929 is an orally active peroxisome proliferator-activated receptor-γ (PPARγ) agonist with a pKi of 8.84 for human PPAR-γ, and pEC50s of 8.56 and 8.27 for human PPAR-γ and murine PPAR-γ, respectively. GW 1929 (hydrochloride) has antidiabetic efficacy and neuroprotective potential .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-114263
CAS No.: 1454925-59-7
Purity:  99.07%
Target:  

PPAR

Research Areas:  

Cancer

NXT629 is a potent, selective, and competitive PPAR-α antagonist, with an IC50 of 77 nM for human PPARα, shows high selectivity over other nuclear hormone receptor, such as PPARδ, PPARγ, ERβ, GR and TRβ, IC50s are 6.0, 15, 15.2, 32.5 and >100 μM, respectively . NXT629 has potent anti-tumor activity and inhibits experimental metastasis of cancer cell in animal models .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-B0287
CAS No.: 637-07-0
Target:  

PPAR

Research Areas:  

Metabolic Disease

Clofibrate is an agonist of PPAR, with EC50s of 50 μM, ~500 μM for murine PPARα and PPARγ, and 55 μM, ~500 μM for human PPARα and PPARγ, respectively.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-15697
CAS No.: 1402601-82-4
Purity:  99.07%
Research Areas:  

Metabolic Disease

TUG-770 is a potent, selective and orally active GPR40/FFA1 agonist with an EC50 of 6 nM for human FFA1. TUG-770 shows a high selectivity for FFA1 over FFA2, FFA3, FFA4, PPARγ, other receptors, transporters, and enzymes. TUG-770 can be uesd for type 2 diabetes research . TUG-770 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-10678
CAS No.: 1000998-59-3
Purity:  99.31%
Target:  

PPAR

Research Areas:  

Cardiovascular Disease

BMS-687453 is a potent and selective PPARα agonist, with an EC50 and IC50 of 10 nM and 260 nM for human PPARα and 4100 nM and >15000 nM for PPARγ in PPAR-GAL4 transactivation assays.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-A0087
CAS No.: 6197-30-4
Octocrylene is an organic ultraviolet (UV) filter that absorbs mainly UVB radiation and shorter UVA wavelengths. Octocrylene acts as a partial agonist of PPARγ, which alters the gene transcription profile of lipid metabolism enzymes. In addition, Octocrylene is cytotoxic and genotoxic to human skin fibroblasts and mediates the biosynthesis of estrogens such as estriol in zebrafish larvae, while affecting antioxidant pathways including glutathione transferase and peroxisomes .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-16086
CAS No.: 199113-98-9
Synonyms: DRF 2593; NN 2344
Target:  

PPAR

Research Areas:  

Metabolic Disease

Balaglitazone is a selective partial PPARγ agonist with an EC50 of 1.351 μM for human PPARγ.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-21191
CAS No.: 375-73-5
Synonyms: PFBS
Perfluorobutanesulfonic acid (PFBS) is a short-chain perfluoroalkyl substance and the main replacement for perfluorooctanesulfonic acid. Perfluorobutanesulfonic acid induces fat accumulation in human HepG2 hepatoma cells. Perfluorobutanesulfonic acid promotes lipid accumulation by activating PPARγ pathway and triggering oxidative stress, endoplasmic reticulum stress and calcium dyshomeostasis. Perfluorobutanesulfonic acid impairs reproduction and causes developmental disorders in offspring of Caenorhabditis elegans. Perfluorobutanesulfonic acid disrupts pancreatic organogenesis and lipid homeostasis in zebrafish embryos. Perfluorobutanesulfonic acid can be used in environmental toxicology, lipid metabolism and developmental toxicity studies .
loading...
    loading...
Cat. No.: HY-17444
CAS No.: 251565-85-2
Target:  

PPAR

Research Areas:  

Metabolic Disease Cancer

Tesaglitazar is a dual-target PPARα/γ agonist with an EC50 of 13.4 μM for rat PPARα and 3.6 μM for human PPARα. Tesaglitazar affects lipid and glucose metabolism by activating PPARα and PPARγ receptors, and has the potential to improve blood sugar and relieve pain. Tesaglitazar can be used to induce in vivo tumor models and can be used in the study of type 2 diabetes, dyslipidemia, and neuropathic pain .
loading...
    loading...
Cat. No.: HY-148351
CAS No.: 420826-65-9
Purity:  98.07%
Target:  

PPAR

Research Areas:  

Cancer

BAY-0069 is a potent and selective PPARγ inverse agonist with an IC50 value of 6.3 nM and 24 nM for human PPARγ and mouse PPARγ. BAY-0069 can be used to research cancer .
loading...
    loading...
Cat. No.: HY-111254
CAS No.: 870554-67-9
Purity:  98.88%
Target:  

PPAR NF-κB JNK

Research Areas:  

Inflammation/Immunology

GQ-16 is an orally active PPARγ partial agonist with an IC50 of 1.84 μM and a Ki of 160 nM against human PPARγ. GQ-16 inhibits Cdk5-mediated Ser-273 phosphorylation. GQ-16 improves insulin sensitivity and glucose tolerance in obese and diabetic mice. GQ-16 also exhibits certain cytotoxicity against tumor cells. GQ-16 can be used in research related to obesity, diabetes and cancer .
loading...
    loading...
Cat. No.: HY-17445
CAS No.: 331741-94-7
Synonyms: BMS-298585
Target:  

PPAR

Muraglitazar (BMS-298585) is an orally active non-thiazolidinedione oxybenzylglycine dual-target PPARα/PPARγ agonist, with an IC50 of 0.25 μM and an EC50 of 0.32 μM against human PPARα, and an IC50 of 0.19 μM and an EC50 of 0.11 μM against human PPARγ. Muraglitazar regulates lipid homeostasis, enhances peripheral insulin sensitivity, and improves β-cell function. Muraglitazar reduces levels of blood glucose, insulin, triglycerides and free fatty acids, normalizes adiponectin and corticosterone levels, promotes cholesterol efflux, reduces hepatic lipid content, regulates body weight, prevents hyperglycemia, and improves glucose tolerance. Muraglitazar can be used in research related to type 2 diabetes and dyslipidemia .
loading...
    loading...
Cat. No.: HY-B1787
CAS No.: 59973-80-7
Research Areas:  

Cancer

Sulindac sulfone is an orally active metabolite of Sulindac (HY-B0008). Sulindac sulfone activates PPARγ and drives transcriptional induction of SSAT by binding to the PPRE-2 element. Sulindac sulfone induces Apoptosis. Sulindac sulfone negatively regulates the function of VDAC1/2 to inhibit the mTORC1 pathway, reduces Cyclin D1 levels, and induces G1 cell cycle arrest in colon cancer cells. Sulindac sulfone exerts colon cancer preventive effects through a COX-independent mechanism. Sulindac sulfone can be used in research related to colon cancer .
loading...
    loading...